Such strategies are typically based on paradigms of increasing the tumor mutational burden (TMB) and resulting tumor-associated neoantigens (20), or increasing type I IFN expression through nucleic acid–driven cGAS/STING activation (21). The gene discussed is STING1; the disease is neoplasm.